Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes as measured by the time to first event in the CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. To assess the effect of treatment with MK-3102 25 mg q.w. compared with placebo on A1C at 4 months. To demonstrate the non-inferiority of MK-3102 (omarigliptin) compared with placebo (against a background of standard of care) on the time to first occurrence in the composite endpoint of cardiovascular death, nonfatal MI or non-fatal stroke.
Critère d'inclusion
- Type 2 diabetes mellitus